← Leaderboards
Aileen Chang
George Washington University
$3,335,599
Attributed
$5,853,679
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,853,679 · 3
By mechanism
U01$5,036,160 · 1
K23$465,522 · 1
R34$351,997 · 1
Top collaborators
- Gary Steven Firestein5 shared
Most similar at George Washington University
Same institution · by research overlap
- Maria Cecilia Zea$7,835,516
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesCulicidaeChronicChikungunya VirusArthritisInfectionInflammatoryChikungunyaEvidence Based TreatmentCytokineViral ArthritisMediatingAffectRheumatoid ArthritisInfiltrationRheumatologyDisease OutbreaksEvidence BaseChikungunya InfectionStandard CareAlphavirusDoseTherapeutic TargetOral
Grant awards (9)
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection$1,546,361
U01 · FY2024 · AR · contact PI
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection$148,419
U01 · FY2024 · AR · contact PI
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection$1,492,743
U01 · FY2023 · AR · contact PI
Cutting Edge Pain Research in the Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH) Trial$259,670
U01 · FY2023 · AR · contact PI
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection$1,588,967
U01 · FY2022 · AR · contact PI
The role of IL-2 therapy for Relapsing-Remitting Chikungunya Arthritis$155,174
K23 · FY2022 · AR · contact PI
The role of IL-2 therapy for Relapsing-Remitting Chikungunya Arthritis$155,174
K23 · FY2021 · AR · contact PI
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection$351,997
R34 · FY2020 · AR · contact PI
The role of IL-2 therapy for Relapsing-Remitting Chikungunya Arthritis$155,174
K23 · FY2020 · AR · contact PI